Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Clarient launches Clarient Insight Dx Pulmotype Test for lung cancer

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of a new lung cancer test, Clarient Insight® Dx Pulmotype® Test, that helps physicians classify specific types of lung cancer to identify which therapies may be most effective.

10 Feb 2010

Autism Speaks: Ten most significant autism research achievements in 2009

Autism Speaks, the world's largest autism science and advocacy organization has released its annual list of the 10 most significant research achievements to have impacted autism during the previous year. Every year, Autism Speaks documents the progress made toward its mission to discover the causes and treatment for autism spectrum disorders, and compiles a list of the 10 most significant research achievements to have impacted autism during the previous year.

10 Feb 2010

Elan announces fourth-quarter and full-year financial results ended December 31, 2009

Elan Corporation, plc today reported its fourth quarter and full-year 2009 financial results and provides financial guidance for 2010.

10 Feb 2010

Dana-Farber Cancer Institute, Sanford-Burnham Medical Research Institute sign license agreement with Genentech, Roche

10 Feb 2010

Johns Hopkins Hospital initiates Phase I trial with Neogenix's NPC-1C

Neogenix Oncology, Inc. (Neogenix) announced today that the Johns Hopkins Hospital has initiated a Phase I trial with the company’s first therapeutic antibody, NPC-1C, in patients with late stage pancreatic or colorectal cancer.

10 Feb 2010

NIAID awards Tulane University over $15M to develop Lassa fever vaccine and treatment

The National Institute of Allergies and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded a five-year contract totaling $15,254,919 to Tulane University for its ongoing efforts to treat and prevent Lassa fever, an often deadly viral disease that threatens hundreds of thousands of people annually in West Africa and is classified as a potential bioterrorism threat.

10 Feb 2010

Biogen Idec reports 2009 fourth quarter and full year earnings

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its full year and fourth quarter 2009 results.

9 Feb 2010

Thrombogenics announces publication of positive microplasmin Phase II trial results

ThromboGenics NV, a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announces today that the positive microplasmin Phase II trial results, evaluating the product's efficacy and safety in patients who require vitrectomy, have been published in the prestigious American Academy of Ophthalmology's Journal, Ophthalmology, the leading journal for the vitreoretinal community.

9 Feb 2010

Advanced paternal age increases autism risk only when the mother is younger

Advanced maternal age is linked to a significantly elevated risk of having a child with autism, regardless of the father's age, according to an exhaustive study of all births in California during the 1990s by UC Davis Health System researchers. Advanced paternal age is associated with elevated autism risk only when the father is older and the mother is under 30, the study found.

9 Feb 2010

NIH awards over $15M for Tulane University's collaborative effort to combat VHF

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, and Tulane University, today announced a major extension of the collaborative effort to combat viral hemorrhagic fever (VHF), an effort that will generate an additional $800,000 in contract revenue for Corgenix over the life of the contract.

9 Feb 2010

Denosumab exhibits superiority over Zometa in treatment of prostate cancer men with bone metastases

Amgen today announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa® (zoledronic acid) in the treatment of bone metastases in 1,901 men with advanced prostate cancer met its primary and secondary endpoints.

9 Feb 2010

Novavax announces new data from trivalent seasonal influenza VLP vaccine study

Novavax, Inc. announced today new data from a clinical study that began in May of 2009 among healthy adults 18 to 49 years of age with Novavax's trivalent seasonal influenza Virus-like Particle (VLP) vaccine. The vaccine matched the influenza strains recommended for the 2008-2009 influenza season including H1N1 A/Brisbane/59/2007, H3N2 A/Brisbane/10/2007, and B/Florida/04/2006 strains.

9 Feb 2010

Dana-Farber Cancer Institute and Sanford-Burnham Medical Research Institute sign license agreement with Genentech

Dana-Farber Cancer Institute and the Sanford-Burnham Medical Research Institute have signed a license agreement with Genentech, a wholly owned member of the Roche group, and Roche, that grants the companies exclusive rights to manufacture, develop and market human monoclonal antibodies to treat and protect against group 1 influenza viruses. These viruses include the strains for the current seasonal and H1N1 influenzas. Genentech and Roche also have a non-exclusive right to manufacture, develop and market diagnostic tests for group 1 influenza.

9 Feb 2010

GeoVax Labs provides updates on HIV-1 vaccine trials

GeoVax Labs, Inc., an Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, today provided an update on its vaccine trials progress.

9 Feb 2010

Plant-produced antibodies can help prevent infection

The first head-to-head comparison of therapeutic monoclonal antibodies produced from plants versus the same antibodies produced from mammalian cells has shown that plant-produced antibodies can fight infection equally well.

9 Feb 2010

AnaptysBio, Merck announce strategic collaboration to develop novel antibody therapeutics

AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, today announced a strategic collaboration with Merck, through an affiliate, to develop novel antibody therapeutics to a specified disease target.

8 Feb 2010

Inovio Biomedical announces additional immunogenicity data from therapeutic cervical cancer vaccine trial

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today additional interim safety and immunogenicity data from its therapeutic cervical cancer vaccine (VGX-3100) trial. VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18 and is delivered via in vivo electroporation.

8 Feb 2010

FDA grants Talecris Biotherapeutics orphan drug designation for Alpha1-Proteinase Inhibitor to treat AAT deficiency

Talecris Biotherapeutics, Inc. announced today that it was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the development of an aerosol formulation of Alpha1-Proteinase Inhibitor (Human, A1PI) to treat congenital alpha1-antitrypsin (AAT) deficiency. AAT deficiency is a chronic, hereditary condition that increases the risk of certain diseases, especially emphysema, which typically emerges in the fourth decade of life. Currently, there are no approved, inhaled treatments available for the treatment of AAT deficiency.

5 Feb 2010

Research could help in developing protein-based vaccine against maternal malaria

Researchers at the University of Copenhagen have become the first in the world to synthesize the entire protein that is responsible for life-threatening malaria in pregnant women and their unborn children.

5 Feb 2010

Early stage trial finds malaria vaccine effectively protected young children, study says

An experimental vaccine was found to effectively protect young children from malaria in Mali, Reuters reports. According to the news service, "The vaccine, which uses an immune system booster called an adjuvant from British drugmaker GlaxoSmithKline, targets the malaria parasite as it is actively infecting red blood cells and causing fever and illness" (Steenhuysen, 2/3).

5 Feb 2010

Antibody News and Research

Further Reading

Clarient launches Clarient Insight Dx Pulmotype Test for lung cancer

Autism Speaks: Ten most significant autism research achievements in 2009

Elan announces fourth-quarter and full-year financial results ended December 31, 2009

Dana-Farber Cancer Institute, Sanford-Burnham Medical Research Institute sign license agreement with Genentech, Roche

Johns Hopkins Hospital initiates Phase I trial with Neogenix's NPC-1C

NIAID awards Tulane University over $15M to develop Lassa fever vaccine and treatment

Biogen Idec reports 2009 fourth quarter and full year earnings

Thrombogenics announces publication of positive microplasmin Phase II trial results

Advanced paternal age increases autism risk only when the mother is younger

NIH awards over $15M for Tulane University's collaborative effort to combat VHF

Denosumab exhibits superiority over Zometa in treatment of prostate cancer men with bone metastases

Novavax announces new data from trivalent seasonal influenza VLP vaccine study

Dana-Farber Cancer Institute and Sanford-Burnham Medical Research Institute sign license agreement with Genentech

GeoVax Labs provides updates on HIV-1 vaccine trials

Plant-produced antibodies can help prevent infection

AnaptysBio, Merck announce strategic collaboration to develop novel antibody therapeutics

Inovio Biomedical announces additional immunogenicity data from therapeutic cervical cancer vaccine trial

FDA grants Talecris Biotherapeutics orphan drug designation for Alpha1-Proteinase Inhibitor to treat AAT deficiency

Research could help in developing protein-based vaccine against maternal malaria

Early stage trial finds malaria vaccine effectively protected young children, study says

A new way of characterising biomolecules eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest Life Science News